SHR-A2102 + osimertinib

SHR-A2102 + osimertinib is a combination therapy consisting of **SHR-A2102**, an antibody-drug conjugate targeting nectin-4, and **osimertinib**, a third-generation small molecule tyrosine kinase inhibitor targeting mutant forms of the epidermal growth factor receptor (EGFR). SHR-A2102 delivers cytotoxic payload to nectin-4–expressing tumor cells, resulting in targeted tumor cell death, while osimertinib selectively inhibits both EGFR-activating mutations and T790M resistance mutations, thereby blocking EGFR-mediated signaling and proliferation in cancer cells. This combination is under investigation primarily for advanced and metastatic **solid tumors** and especially non-small cell lung cancer (NSCLC) with EGFR mutations. SHR-A2102 is being developed by Hengrui/Merck KGaA, with clinical trials in advanced solid tumors. Osimertinib (Tagrisso) is developed and marketed by AstraZeneca for NSCLC with EGFR mutations[1][2][3][5][6][7][8].

Other names

anti-nectin-4 antibody-drug conjugate SHR-A2102anti-nectin4 antibody-drug conjugate SHR-A2102anti-nectin 4 antibody-drug conjugate SHR-A2102